6-(三氟甲基)喹啉-4-醇 | 49713-51-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-(三氟甲基)喹啉-4-醇
• 中文别名: 4-羟基-6-三氟甲基喹啉；6-三氟甲基喹啉-4-醇；4-羟基-2-三氟甲基喹啉；6-(三氟甲基)-4-喹啉
• 英文名称: 6-(trifluoromethyl)quinolin-4-ol
• 英文别名: 4-hydroxy-6-(trifluoromethyl)quinoline；6-(trifluoromethyl)-1H-quinolin-4-one
• CAS: 49713-51-1
• 化学式: C₁₀H₆F₃NO
• mdl: MFCD22560350
• 分子量: 213.159
• InChiKey: CEIVPELVRVTMJW-UHFFFAOYSA-N

物化性质

• 熔点：
  265 °C
• 稳定性/保质期：
  如果按照规定使用和储存，则不会分解，也没有已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请保持贮藏器密封，并将其存放在阴凉、干燥处。确保工作环境具备良好的通风或排气设施。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
6-(Trifluoromethyl)quinolin-4-ol
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
6-(Trifluoromethyl)quinolin-4-ol
Ingredient name:
CAS number: 49713-51-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H6F3NO
Molecular weight: 213.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-(三氟甲基)喹啉-4-醇 在 三氯氧磷 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.5h， 以31%的产率得到4-氯-6-(三氟甲基)喹啉
  参考文献：
  名称：

  具有肿瘤富集药代动力学的 CDK8/19 介质激酶的选择性和口服生物利用度喹啉-6-腈基抑制剂

  摘要：

  Senexins 是 CDK8/19 介质激酶的强效选择性喹唑啉抑制剂。为了提高其效力和代谢稳定性，基于 Senexin A 和 Senexin B 的模拟药物-靶点对接模型，通过结构导向策略设计了基于喹啉的衍生物。合成了喹啉-Senexin 衍生物库以探索结构-活动关系（SAR）。优化的化合物20a(Senexin C) 具有高选择性的强效 CDK8/19 抑制活性。与原型抑制剂 Senexin B 相比，Senexin C 代谢更稳定，对 CDK8/19 依赖性细胞基因表达的抑制作用更持久。使用基于肿瘤的新型 PD 测定法进行体内药代动力学 (PK) 和药效学 (PD) 评估表明 Senexin C 具有良好的口服生物利用度，具有很强的肿瘤富集 PK 特征和肿瘤 PD 标志物反应。Senexin C 在全身性体内模型中抑制 MV4-11 白血病生长，具有良好的耐受性。

  DOI：

  10.1021/acs.jmedchem.1c01951
• 作为产物：
  描述：

  2,2-dimethyl-5-[[4-(trifluoromethyl)anilino]methylene]-1,3-dioxane-4,6-dione 在 二苯醚 作用下， 反应 1.5h， 生成 6-(三氟甲基)喹啉-4-醇
  参考文献：
  名称：

  通过钯催化的CH官能团将喹诺酮类直接C-3-烯基化

  摘要：

  据报道，钯负载量为1％时，钯催化的CH官能化使喹诺酮类化合物的C-3-烯基化程度达到前所未有的水平。该方法为生产各种新的喹诺酮衍生物提供了有效的途径。

  DOI：

  10.1002/adsc.201000364

文献信息

• A visible-light-irradiated electron donor-acceptor complex-promoted radical reaction system for the C H perfluoroalkylation of quinolin-4-ols
  作者：Yunze Li、Min Rao、Zhenwei Fan、Baoyi Nian、Yaofeng Yuan、Jiajia Cheng

  DOI：10.1016/j.tetlet.2019.151046

  日期：2019.9

  An efficient method for visible-light-induced perfluoroalkylaion of quinolin-4-ol has been reported. In the presence of t-BuONa and perfluoroalkyl iodide, quinolin-4-ol underwent CH perfluoroalkylation under the irradiation of green light. Mechanistic studies demonstrated that visible-light promoted intermolecular charge transfer within the transient electron donor-acceptor complex in the absence of

  已经报道了可见光诱导的喹啉-4-醇全氟烷基阴离子的有效方法。在t- BuONa和全氟烷基碘的存在下，喹啉-4-醇在绿光照射下经历了C H全氟烷基化。机理研究表明，在没有任何光催化剂的情况下，可见光促进了瞬态电子供体-受体复合物中分子间的电荷转移。
• CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF
  申请人：SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.

  公开号：US20160108035A1

  公开（公告）日：2016-04-21

  Cycloalkyl acid derivatives, a preparation method thereof, and a pharmaceutical application thereof are described. In particular, a cycloalkyl acid derivative represented by general formula (I) and a medical salt thereof, a preparation method thereof, and an application of the cycloalkyl acid derivative and the medical salt thereof as URAT1 inhibitors, and particularly as therapeutic agents for diseases related to an abnormal uric acid level are described, wherein definitions of substituent groups in general formula (I) are the same as the definitions in the specification.

  描述了环烷基酸衍生物及其制备方法和药物应用。具体地，描述了一种由通式（I）表示的环烷基酸衍生物及其医用盐，其制备方法，以及将该环烷基酸衍生物和医用盐作为URAT1抑制剂的应用，特别是作为治疗与异常尿酸水平相关疾病的药物。其中，通式（I）中取代基团的定义与说明书中的定义相同。
• [EN] IMMUNOREGULATORY AGENTS<br/>[FR] AGENTS IMMUNORÉGULATEURS
  申请人：FLEXUS BIOSCIENCES INC

  公开号：WO2016073770A1

  公开（公告）日：2016-05-12

  Compounds that modulate the oxidoreductase enzyme indoleamine 2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

  本文描述了调节氧化还原酶酶色氨酸2,3-二氧化酶的化合物，以及含有这些化合物的组合物。还提供了利用这些化合物和组合物治疗和/或预防多种疾病、紊乱和症状的用途，包括由色氨酸2,3-二氧化酶介导的癌症和免疫相关紊乱。
• 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
  申请人：SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드(520080332544)

  公开号：KR20160006207A

  公开（公告）日：2016-01-18

  본 발명은 사이클로알킬산 유도체, 그의 제조 방법 및 그의 약학적 용도에 관한 것이며, 특히 본 발명은 하기 화학식 I에 의해 나타내는 사이클로알킬산 유도체 및 그의 의학적 염, 그의 제조 방법, 및 URAT1 억제제로서 및 특히 이상 요산 수준과 관련된 질병에 대한 치료제로서 상기 사이클로알킬산 유도체 및 그의 의학적 염의 용도에 관한 것이며, 여기에서 화학식 I의 치환체 그룹들의 정의는 명세서에서의 정의와 같다. 화학식 I

  这是一段关于某种环丙基酸衍生物的专利描述，涉及其制备方法和药用用途，特别是涉及由化学式I表示的环丙基酸衍生物及其医药盐、制备方法，以及作为URAT1抑制剂和特别是用于治疗与高尿酸水平相关的疾病的药物的用途。在此，化学式I中的取代基团的定义与规范中的定义相同。 化学式I
• Highly Enantioselective Catalytic Addition of Grignard Reagents to N‐Heterocyclic Acceptors
  作者：Yafei Guo、Syuzanna R. Harutyunyan

  DOI：10.1002/anie.201906237

  日期：2019.9.9

  greatly sought after because of their significance in medicinal chemistry. Described here is the first general catalytic methodology to access a wide variety of chiral 2‐ and 4‐substituted tetrahydro‐quinolones, dihydro‐4‐pyridones, and piperidones with excellent yields and enantioselectivities, utilizing a single catalyst system.

  由于手性N-杂环分子支架在药物化学中的重要性，因此备受追捧。这里描述的是第一种通用催化方法，它利用单一催化剂系统，以优异的收率和对映选择性获得了各种手性2和4取代的四氢喹诺酮，二氢4吡啶酮和哌啶酮。